Metagenomi Therapeutics

MGX

Market cap $60.1M

New name reflects the Company's strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs); MGX-001 on track for IND/CTA submissions in 4Q 2026 Cash runway anticipated through 4Q 2027 EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that it has completed its corporate name change to Metagenomi Therapeutics, Inc. to reflect the Company's strategic evolution focused on driving forward the Company's lead program in hemophilia A and other compelling programs and technologies that have the highest probability of near-term success.

EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, MA.

EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D.

Metagenomi, Inc. (NASDAQ:MGX) on Tuesday shared new dose range finding data from its MGX-001 hemophilia A program.

Metagenomi (MGX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.45 per share a year ago.

New MGX-001 preclinical data supports advancement into clinical development;  Demonstrated curative FVIII activity in non-human primates

MGX-001 demonstrated curative FVIII activity in non-human primates Pre-IND regulatory meeting expected in Q4 2025 with investigational new drug (IND) and clinical trial application (CTA) submissions expected in 4Q 2026 EMERYVILLE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today reported new dose range finding data from the Company's MGX-001 hemophilia A program.

Biotech firm Metagenomi said it is using artificial intelligence chips from Amazon.com's cloud computing unit to power some of its work in developing gene-editing technologies.

Does Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Metagenomi (MGX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.29 per share a year ago.